VERVE THERAPEUTICS INC (VERV)
US92539P1012 - Common Stock
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of...
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws
/PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is...
Commit To Purchase Verve Therapeutics At $5, Earn 14.9% Annualized Using Options
After a Serious Setback, Is Verve Therapeutics a Buy?
There are a few silver linings at play here.
Verve Therapeutics Enters Oversold Territory (VERV)
Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects
The company is now pausing enrollment in the study of its lead asset, VERVE-101.
Verve Pauses Gene-Editing Trial for High Cholesterol Treatment
Verve Therapeutics Inc. shares tumbled in premarket trading after it cited safety concerns for pausing enrollment in a study of its gene-editing treatment for people with high cholesterol, delivering a setback to the promising new field of medicine.
Verve Therapeutics Announces Updates on its PCSK9 Program
Verve Therapeutics Announces Updates on its PCSK9 Program
Heart-1 clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg of VERVE-101 Company to pause enrollment in Heart-1 clinical trial...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of...
Commit To Purchase Verve Therapeutics At $10, Earn 22.4% Annualized Using Options
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks.
VERV Crosses Below Key Moving Average Level
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of...
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders.
Beam stock jumps as Eli Lilly deal brings Q4 beat (NASDAQ:BEAM)
Beam Therapeutics (BEAM) stock gains as the company reports profits in Q4 after boosting revenue thanks to a collaboration deal with Eli Lilly (LLY). Read more here.
Verve Therapeutics GAAP EPS of -$0.69 beats by $0.13, revenue of $5.14M beats by $3.97M (NASDAQ:VERV)
Verve Therapeutics reports better-than-expected Q4 financial results, with higher revenue and a cash runway extending into late 2026.
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Three Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in 2024 Announced First Human Proof-of-Concept Data for In Vivo Base Editing from...
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts.
3 Gene Editing Stocks With Unprecedented Surge Potential
While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
It's less scary to take on risky investments when the market is rising.
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
BOSTON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of...